Drugs Containing Excipient (Inactive Ingredient) POLOXAMER 237

Branded drugs containing POLOXAMER 237 excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Xttrium Laboratories Inc	HIBICLENS	chlorhexidine gluconate 4%	0116-0575	POLOXAMER 237
Molnlycke Health Care	HIBICLENS	chlorhexidine gluconate	0234-0575	POLOXAMER 237
A-S Medication Solutions	HIBICLENS	chlorhexidine gluconate	50090-2354	POLOXAMER 237
Georgia-Pacific Consumer Products LP	HIBICLENS FOR GEORGIA PACIFIC	chlorhexidine gluconate	54622-575	POLOXAMER 237
Asclemed USA, Inc.	HIBICLENS	chlorhexidine gluconate	76420-535	POLOXAMER 237

Generic drugs containing POLOXAMER 237 excipient

Company	Ingredient	NDC	Excipient
Xttrium Laboratories Inc	chlorhexidine gluconate 4%	0116-0575	POLOXAMER 237
Molnlycke Health Care	chlorhexidine gluconate	0234-0575	POLOXAMER 237
A-S Medication Solutions	chlorhexidine gluconate	50090-2354	POLOXAMER 237
Georgia-Pacific Consumer Products LP	chlorhexidine gluconate	54622-575	POLOXAMER 237
Asclemed USA, Inc.	chlorhexidine gluconate	76420-535	POLOXAMER 237

Market Dynamics and Financial Trajectory for POLOXAMER 237

Last updated: February 10, 2026

Overview

POLOXAMER 237 is a non-ionic surfactant, classified within the poloxamer family. Its surfactant properties facilitate solubilization, stabilization, and controlled drug release in pharmaceutical formulations. The compound’s broad applicability in drug delivery, cosmetics, and personal care products influences its market dynamics and financial prospects.

Market Size and Growth Drivers

The global pharmaceutical excipient market was valued at approximately $7.95 billion in 2021, with surfactants comprising a significant segment. The overall pharmaceutical excipient market is expected to grow at a compound annual growth rate (CAGR) of around 6% from 2022 to 2030 [1].

POLOXAMER 237's market share remains specialized, primarily driven by:

• Formulation innovation: The shift toward targeted and controlled-release drug delivery systems favors excipients with solubilizing capabilities.
• Biocompatibility and safety profiles: Its non-toxic, non-ionic nature aligns with regulatory preferences for excipients.
• Growing biologics and biosimilars markets: These formulations often require solubilization agents like POLOXAMER 237.

Competitive Landscape

Major manufacturers include BASF, Ashland, and Croda International, who manufacture and supply poloxamers. Market entry barriers are high due to manufacturing complexity, regulatory compliance, and customer loyalty to established suppliers.

Pricing and Revenue Trajectory

Pricing of POLOXAMER 237 varies depending on purity, batch size, and regional market conditions. Estimated average price ranges from $10 to $30 per kilogram globally.

Historical revenue data from key suppliers indicate:

Company	2020 Revenue from Poloxamers	2021 Revenue from Poloxamers	YoY Growth
BASF	~$200 million	~$210 million	5%
Ashland	~$150 million	~$160 million	6.7%

The revenue growth aligns with overall excipient market expansion, though POLOXAMER 237's niche status limits its share.

Regulatory Factors

Stringent pharmacopeial standards and requirements from agencies like the FDA and EMA affect commercialization. POLOXAMER 237's safety profile simplifies approval processes, though regional guidelines impact supply chain and pricing.

R&D and Innovation Trends

Investments focus on:

• Enhancing solubility and stability parameters.
• Developing derivatives with tailored properties.
• Integrating POLOXAMER 237 into nanocrystals and liposomal systems.

These innovations extend product utility and support premium pricing.

Financial Outlook

In the near term (2023–2027), revenue from POLOXAMER 237 is projected to increase at a CAGR of approximately 4-6%, driven by:

• Expansion in biologics requiring surfactants.
• Adoption in new markets like gene therapy.
• Regulatory approvals of novel formulations that incorporate POLOXAMER 237.

Major suppliers anticipate annual revenues in excess of $300 million globally by 2027, assuming continued growth and product diversification.

Challenges

• Supply chain disruptions affecting raw materials.
• Price pressures stemming from increased competition.
• Regulatory hurdles in emerging markets.

Opportunities

• Developing high-purity grades tailored for specific delivery systems.
• Formulating combination excipients for multifunctional roles.
• Entering emerging markets with growing pharmaceutical sectors.

Key Takeaways

• POLOXAMER 237 operates within a niche but expanding segment of the pharmaceutical excipient market.
• The compound’s growth depends on formulation innovations and increasing biologics adoption.
• Revenue prospects remain favorable, with steady annual growth and potential for market expansion.
• Competition and regulatory landscape influence pricing and supply chain considerations.
• R&D efforts focusing on derivative development can create new revenue streams.

FAQs

1. What are the primary applications of POLOXAMER 237?
It is mainly used in drug solubilization, stabilization of formulations, and controlled-release systems in pharmaceuticals, as well as in cosmetics and personal care products.

2. How does POLOXAMER 237 compare price-wise to other excipients?
It generally costs $10-$30 per kilogram, higher than some traditional excipients like sodium chloride but justified by its specialized functionality and safety profile.

3. What regions are the largest markets for POLOXAMER 237?
North America and Europe lead due to mature pharmaceutical industries. Asia-Pacific shows rapid growth driven by expanding manufacturing bases and increasing biologics development.

4. Are there significant regulatory hurdles for POLOXAMER 237?
No major hurdles exist; it has a well-established safety profile. However, regional standards may require specific documentation and compliance.

5. What innovations could influence POLOXAMER 237's market trajectory?
Development of derivatives with enhanced solubilization capacity, integration into nanocarriers, and formulation of combined excipients.

References

[1] MarketsandMarkets, "Pharmaceutical Excipients Market," 2022.